Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension.
Phase of Trial: Phase IV
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Candesartan cilexetil (Primary) ; Candesartan cilexetil/hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Takeda Pharma
- 12 Jul 2010 Actual patient number (107) added as reported by ClinicalTrials.gov.
- 12 Jul 2010 Actual end date added to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 12 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.